Claims
- 1. A compound having the formula: ##STR8## wherein: R.sub.1 and R.sub.2 are each independently selected from the group consisting of H, loweralkyl, aryl, alkylaryl, aminoalkyl, aminoaryl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl;
- R.sub.3 and R.sub.4 are each independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkylaryl, aryl, oxyaryl, aminoalkyl, aminoaryl, or halogen; and
- X and Y are located in the para or meta positions and are each ##STR9## wherein: each R.sub.5 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl or two R.sub.5 groups together represent C.sub.2 to C.sub.10 alky, hydroxyalkyl, or alkylene; and
- R.sub.6 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, cycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aryl, or alkylaryl;
- or a pharmaceutically acceptable salt thereof.
- 2. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR10## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is isoalkyl;
- and the pharmaceutically acceptable salts thereof.
- 3. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR11## wherein: R.sub.1 is H, R.sub.2 is H, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is C.sub.3 -C.sub.8 alkoxyalkyl; and the pharmaceutically acceptable salts thereof.
- 4. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR12## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is hydroxyalkyl;
- and the pharmaceuticallyacceptable salts thereof.
- 5. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR13## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is propoxyethyl;
- and the pharmaceutically acceptable salts thereof.
- 6. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR14## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is propoxyisopropyl;
- and the pharmaceutically acceptable salts thereof.
- 7. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR15## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is aryl or alkylaryl;
- and the pharmaceutically acceptable salts thereof.
- 8. A compound according to claim 1, wherein X and Y are located in the para position and are each: ##STR16## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is alkoxycycloalkyl;
- and the pharmaceutically acceptable salts thereof.
- 9. A compound according to claim 1, said compound selected from the group consisting of:
- 2,4-bis(4-guanylphenyl)furan,
- 2,4-bis(4-guanylphenyl)-3,5-dimethylfuran,
- 2,4-di-p[2(3,4,5,6-tetrahydropyrimidyl)phenyl]furan,
- 2,4-bis[4-(2-imidazolinyl)phenyl]furan,
- 2,4-bis[4-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl)phenyl]furan,
- 2,4-bis(4-N,N-dimethylcarboxhydrazidephenyl)furan,
- 2,4-bis[4-(N-isopropylamidino)phenyl]furan,
- 2,4-bis{4-[3-(dimethylaminopropyl)amidino]phenyl}furan,
- 2,4-bis-{4-[N-(3-aminopropyl)amidino]phenyl}furan,
- 2,4-bis[2-(imidzaolinyl)phenyl]-3,5-bis(methoxymethyl)furan,
- 2,4-bis[4-N-(dimethylaminoethyl)guanyl]phenylfuran,
- 2,4-bis-{4-[(N-2-hydroxyethyl)guanyl]phenyl}furan,
- 2,4-bis-[4-N-(cyclopropylguanyl)phenyl]furan,
- 2,4-bis-[4-(N,N-diethylaminopropyl)guanyl]phenylfuran,
- 2,4-bis-{4-[N-(3-pentylguanyl)]}phenylfuran, and
- 2,4-bis[4-(N-isopropylamidino)phenyl]-5-methylfuran,
- or the pharmaceutically acceptable salts thereof.
- 10. A compound according to claim 1, said compound selected from the group consisting of:
- 2,4-Bis[4-{(amidino)phenyl}]furan;
- 2,4-Bis[4-{N-(i-propylamidino)phenyl}]furan;
- 2,4-Bis[4-{N-(cyclopentylamidino)phenyl}]furan;
- 2,4-Bis[4,5-dihydro-1H-imidazol-2-yl)phenyl]furan;
- 2,4-Bis[4-{N-(i-butylamidino)phenyl}]furan; and
- 2,4-Bis[4-{N,N-dimethylamino)propylamidino)phenyl}]furan; or the pharmaceutically acceptable salts thereof.
- 11. A method of treating Pneumocystis carinii pneumonia in a subject in need of such treatment, comprising administering to said subject a compound having the formula: ##STR17## wherein: R.sub.1 and R.sub.2 are each independently selected from the group consisting of H, loweralkyl, aryl, alkylaryl, aminoalkyl, aminoaryl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl;
- R.sub.3 and R.sub.4 are each independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkylaryl, aryl, oxyaryl, aminoalkyl, aminoaryl, or halogen; and
- X and Y are located in the para or meta positions and are each selected from the group consisting of H, loweralkyl, oxyalkyl, and ##STR18## wherein: each R.sub.5 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl or two R.sub.5 groups together represent C.sub.2 to C.sub.10 alkyl, hydroxyalkyl, or alkylene; and
- R.sub.6 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, cycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aryl, or alkylaryl;
- or a pharmaceutically acceptable salt thereof, in an amount effective to treat Pneumocystis carinii pneumonia.
- 12. A method according to claim 11, wherein said subject is afflicted with Pneumocystis carinii pneumonia.
- 13. A method according to claim 11, wherein said subject is at risk of developing Pneumocystis carinii pneumonia, said treatment is a prophylactic treatment, and said compound is administered in a prophylactically effective amount.
- 14. A method according to claim 3, wherein X and Y are located in the para or meta positions and are each: ##STR19## and wherein: each R.sub.5 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl or two R.sub.5 groups together represent C.sub.2 to C.sub.10 alkyl, hydroxyalkyl, or alkylene; and
- R.sub.6 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, cycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aryl, or alkylaryl;
- or a pharmaceutically acceptable salt thereof.
- 15. A method according to claim 11, wherein X and Y are in the para position.
- 16. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR20## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is isoalkyl;
- and the pharmaceutically acceptable salts thereof.
- 17. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR21## wherein: R.sub.1 is H, R.sub.2 is H, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is C.sub.3 -C.sub.8 alkoxyalkyl;
- and the pharmaceutically acceptable salts thereof.
- 18. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR22## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is hydroxyalkyl; and the pharmaceutically acceptable salts thereof.
- 19. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR23## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is propoxyethyl;
- and the pharmaceutically acceptable salts thereof.
- 20. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR24## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is propoxyisopropyl;
- and the pharmaceutically acceptable salts thereof.
- 21. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR25## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is aryl or alkylaryl;
- and the pharmaceutically acceptable salts thereof.
- 22. A method according to claim 11, wherein X and Y are located in the para position and are each: ##STR26## wherein: R.sub.1 is H, R.sub.2 is H or loweralkyl, R.sub.3 is H, R.sub.4 is H, R.sub.5 is H, and R.sub.6 is alkylcycloalkyl;
- and the pharmaceutically acceptable salts thereof.
- 23. A method according to claim 11, said compound selected from the group consisting of:
- 2,4-bis(4-guanylphenyl) furan,
- 2,4-bis(4-guanylphenyl)-3 ,5-dimethylfuran,
- 2,4-di-p[2(3,4,5,6-tetrahydropyrimidyl)phenyl]furan,
- 2,4-bis[4-(2-imidazolinyl)phenyl]furan,
- 2,4-bis[4-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl)phenyl]furan,
- 2,4-bis(4-N,N-dimethylcarboxhydrazidephenyl)furan,
- 2,4-bis[4-(N-isopropylamidino)phenyl]furan,
- 2,4-bis{4-[3-(dimethylaminopropyl)amidino]phenyl}furan,
- 2,4-bis-{4-[N-(3-aminopropyl)amidino]phenyl}furan,
- 2,4-bis[2-(imidzaolinyl)phenyl]-3,5-bis(methoxymethyl)furan,
- 2,4-bis[4-N-(dimethylaminoethyl)guanyl]phenylfuran,
- 2,4-bis-{4-[(N-2-hydroxyethyl)guanyl]phenyl}furan,
- 2,4-bis-[4-N-(cyclopropylguanyl)phenyl]furan,
- 2,4-bis-[4-(N,N-diethylaminopropyl)guanyl]phenylfuran,
- 2,4-bis-{4-[N-(3-pentylguanyl)]}phenylfuran, and
- 2,4-bis[4-(N-isopropylamidino)phenyl]-5-methylfuran,
- or the pharmaceutically acceptable salts thereof.
- 24. A method according to claim 11, wherein said compound is selected from the group consisting of:
- 2,4-Bis[4-{(amidino)phenyl}]furan;
- 2,4-Bis[4-{N-(i-propylamidino)phenyl}]furan;
- 2,4-Bis[4-{N-(cyclopentylamidino)phenyl}]furan;
- 2,4-Bis[4,5-dihydro-1H-imidazol-2-yl)phenyl]furan;
- 2,4-Bis[4-{N-(i-butylamidino)phenyl}]furan; and
- 2,4-Bis[4-{N,N-dimethylamino)propylamidino)phenyl}]furan;
- or the pharmaceutically acceptable salts thereof.
Government Interests
The present invention was made with Government support under Grant Number HI-33363 from the National Institutes of Health. The Government has certain rights to this invention.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
3359284 |
Patai et al. |
Dec 1967 |
|
3470151 |
Doyle et al. |
Sep 1969 |
|
5521189 |
Boykin et al. |
May 1996 |
|
5602172 |
Boykin et al. |
Feb 1997 |
|
5667975 |
Dykstra et al. |
Sep 1997 |
|